Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05430763
Other study ID # 5859-19-SMC
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date February 2023
Est. completion date August 2030

Study information

Verified date June 2022
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The current study aims to validate basic research findings of abnormal conductivity and motor abilities from a mouse model in humans. The study will measure nerve conduction properties in WS individuals and characterize motor symptoms in individuals with WS.


Description:

50 individuals with WS will take part in the study. All participants will be recruited from the Williams Syndrome Clinic at Edmond and Lili Safra Children's Hospital, Sheba Medical Center directed by Prof. Doron Gothelf, MD, that coordinates treatment and research of WS in Israel. 20 control age-matched subjects will be recruited as well. A Motor Questionnaire, designed especially for this study will be filled by parents. It includes questions about gross motor, fine motor, gait and coordination characteristics of the children (Bellugi, Bihrle et al. 1990, Wilson, Kaplan et al. 2000, Wilson, Crawford et al. 2009) (General references regarding motor abilities and health). In addition, participants will undergo the following assessments at the neuromuscular clinic and at the movement laboratory, Sheba Medical Center in collaboration with Dr. Amir Dori, Dr. Uri Givon and Dr. Meir Plotnik: (1) nerve conduction study (2) nerve ultrasound (3) neurological assessments (4) GAITRite walkway for gait analysis (5) 3-D motion analysis.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date August 2030
Est. primary completion date August 2030
Accepts healthy volunteers
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: - WS patients. Exclusion Criteria: - WS patients suffering from additional neurological condition (such as epilepsy). - Participants who will have difficulties preforming the tests may ask to be excluded.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Israel Tel Aviv University Tel Aviv

Sponsors (2)

Lead Sponsor Collaborator
Sheba Medical Center Tel Aviv University

Country where clinical trial is conducted

Israel, 

References & Publications (1)

Barak B, Zhang Z, Liu Y, Nir A, Trangle SS, Ennis M, Levandowski KM, Wang D, Quast K, Boulting GL, Li Y, Bayarsaihan D, He Z, Feng G. Neuronal deletion of Gtf2i, associated with Williams syndrome, causes behavioral and myelin alterations rescuable by a remyelinating drug. Nat Neurosci. 2019 May;22(5):700-708. doi: 10.1038/s41593-019-0380-9. Epub 2019 Apr 22. Erratum in: Nat Neurosci. 2019 Jul;22(7):1197. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Nerve conduction test - Amplitude This test's amplitude outcome present a nerve conduction property that can indicate aberrations in signal conduction. 30 days
Primary Nerve conduction test - Latency This test's latency outcome present a nerve conduction property that can indicate aberrations in signal conduction. 30 days
See also
  Status Clinical Trial Phase
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Completed NCT03758651 - Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT02212314 - Response Inhibition Training for Children With Williams Syndrome N/A
Recruiting NCT00768820 - The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome Phase 4
Recruiting NCT04610424 - Cooperative Parent Mediated Therapy in Children With Fragile X Syndrome and Williams Syndrome N/A
Recruiting NCT02706639 - Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
Completed NCT02692846 - WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)
Recruiting NCT06315699 - Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT01132885 - Defining the Brain Phenotype of Children With Williams Syndrome
Completed NCT01864304 - Fat Distribution and Glucose Metabolism in Williams Syndrome N/A
Recruiting NCT02840448 - Impact of Elastin Mediated Vascular Stiffness on End Organs
Recruiting NCT03827525 - Cognitive and Behavioral Therapy of Anxiety in Williams Syndrome
Completed NCT04807517 - Buspirone Treatment of Anxiety in Williams Syndrome Phase 4
Recruiting NCT06087757 - Clemastine Treatment in Individuals With Williams Syndrome Phase 3
Completed NCT00013962 - Vitamin D Metabolism and the Williams Syndrome N/A